Aeglea BioTherapeutics (NASDAQ:AGLE) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) in a report published on Thursday morning. The firm issued a hold rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. Wells Fargo & Company cut their target price on Aeglea BioTherapeutics from $2.00 to $1.50 and set an equal weight rating for the company in a research note on Tuesday, August 9th. Piper Sandler downgraded shares of Aeglea BioTherapeutics from an overweight rating to a neutral rating and reduced their price target for the company from $4.00 to $1.00 in a research note on Thursday, June 2nd. Needham & Company LLC downgraded shares of Aeglea BioTherapeutics from a buy rating to a hold rating in a research note on Thursday, June 2nd. HC Wainwright downgraded shares of Aeglea BioTherapeutics from a buy rating to a neutral rating and lowered their price target for the stock from $17.00 to $1.00 in a report on Thursday, June 2nd. Finally, Jonestrading restated a buy rating and set a $3.00 price objective on shares of Aeglea BioTherapeutics in a research report on Thursday, August 25th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of Hold and an average target price of $1.63.

Aeglea BioTherapeutics Stock Performance

NASDAQ:AGLE opened at $0.48 on Thursday. Aeglea BioTherapeutics has a 52-week low of $0.37 and a 52-week high of $8.50. The stock has a 50-day simple moving average of $0.50 and a 200 day simple moving average of $1.23. The company has a market cap of $29.39 million, a PE ratio of -0.38 and a beta of 1.66.

Aeglea BioTherapeutics (NASDAQ:AGLEGet Rating) last issued its earnings results on Thursday, August 4th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). The firm had revenue of $0.63 million for the quarter, compared to analyst estimates of $1.42 million. Aeglea BioTherapeutics had a negative return on equity of 105.49% and a negative net margin of 1,244.84%. On average, research analysts predict that Aeglea BioTherapeutics will post -1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Marcio Souza acquired 90,000 shares of Aeglea BioTherapeutics stock in a transaction on Thursday, August 25th. The stock was purchased at an average price of $0.56 per share, with a total value of $50,400.00. Following the completion of the purchase, the director now owns 90,000 shares of the company’s stock, valued at approximately $50,400. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aeglea BioTherapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Sio Capital Management LLC lifted its holdings in shares of Aeglea BioTherapeutics by 435.9% in the second quarter. Sio Capital Management LLC now owns 4,668,536 shares of the biotechnology company’s stock valued at $2,358,000 after purchasing an additional 3,797,435 shares in the last quarter. Bain Capital Life Sciences Investors LLC raised its holdings in shares of Aeglea BioTherapeutics by 87.8% in the second quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company’s stock valued at $2,701,000 after purchasing an additional 2,500,000 shares during the last quarter. Pictet Asset Management SA lifted its position in shares of Aeglea BioTherapeutics by 91.6% during the second quarter. Pictet Asset Management SA now owns 4,890,502 shares of the biotechnology company’s stock valued at $2,470,000 after purchasing an additional 2,338,068 shares in the last quarter. Suvretta Capital Management LLC boosted its holdings in Aeglea BioTherapeutics by 57.9% during the first quarter. Suvretta Capital Management LLC now owns 4,059,894 shares of the biotechnology company’s stock worth $9,338,000 after purchasing an additional 1,488,894 shares during the last quarter. Finally, Laurion Capital Management LP increased its position in shares of Aeglea BioTherapeutics by 139.1% during the 4th quarter. Laurion Capital Management LP now owns 1,450,638 shares of the biotechnology company’s stock valued at $6,891,000 after purchasing an additional 844,000 shares during the last quarter. Institutional investors and hedge funds own 81.03% of the company’s stock.

About Aeglea BioTherapeutics

(Get Rating)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.

Featured Stories

Analyst Recommendations for Aeglea BioTherapeutics (NASDAQ:AGLE)

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.